Related Experiment Video
Updated: Jun 22, 2026
07:58
Stromal Vascular Fraction-enriched Fat Grafting for the Treatment of Symptomatic End-neuromata
Published on: November 23, 2017
Mesotherapy for benign symmetric lipomatosis
Toshio Hasegawa1, Tomoyuki Matsukura, Shigaku Ikeda
1Department of Dermatology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan. t-hase@med.juntendo.ac.jp
Aesthetic Plastic Surgery
|June 3, 2009
Summary
Phosphatidylcholine injections offer a promising, less invasive treatment for benign symmetric lipomatosis (Madelung disease). This mesotherapy approach resulted in significant cosmetic improvement for patients with this rare fat disorder.
Area of Science:
- Endocrinology
- Dermatology
- Medical Aesthetics
Background:
- Benign symmetric lipomatosis (Madelung disease) is a rare condition causing abnormal fat distribution, often linked to alcoholism.
- Surgical excision of lipomas in Madelung disease is challenging due to their nonencapsulated nature.
- Conservative treatment options for benign symmetric lipomatosis are infrequently reported.
Observation:
- A 42-year-old male patient presented with multiple, large, symmetrical neck masses characteristic of benign symmetric lipomatosis.
- The patient underwent seven sessions of intralesional phosphatidylcholine injections, administered every four weeks, to induce lipolysis.
- The treatment targeted the lipomatous masses in the neck region.
Findings:
- The phosphatidylcholine injections led to a noticeable improvement in the patient's lipomatosis.
- Significant cosmetic enhancement was achieved following the series of intralesional treatments.
- The lipolysis induced by phosphatidylcholine demonstrated efficacy in reducing lipoma volume.
Implications:
- Intralesional phosphatidylcholine injections (mesotherapy) represent a viable therapeutic alternative for benign symmetric lipomatosis.
- This minimally invasive approach offers potential for improved cosmetic outcomes in Madelung disease patients.
- Further investigation into mesotherapy as a standard treatment for benign symmetric lipomatosis is warranted.
